HK1063467A1 - Spiro-hydantoin compounds useful as anti-inflammatory agents - Google Patents

Spiro-hydantoin compounds useful as anti-inflammatory agents

Info

Publication number: HK1063467A1
Authority: HK; Hong Kong
Prior art keywords: spiro; inflammatory agents; compounds useful; hydantoin compounds; hydantoin
Prior art date: 2001-10-01

Application number

HK04106189.4A

Other languages

English (en)

Inventor

Michele Launay

Magaili Jeannine Blandine Maillet

Eric Antoine Nicolai

Edwin J Iwanowicz

T G Murali Dhar

Dominique Potin

Original Assignee

Bristol Myers Squibb Co

Cerep Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-01

Filing date

2004-08-18

Publication date

2004-12-31

2004-08-18 Application filed by Bristol Myers Squibb Co, Cerep Sa filed Critical Bristol Myers Squibb Co

2004-12-31 Publication of HK1063467A1 publication Critical patent/HK1063467A1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)

HK04106189.4A 2001-10-01 2004-08-18 Spiro-hydantoin compounds useful as anti-inflammatory agents HK1063467A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32636101P	2001-10-01	2001-10-01
US35411302P	2002-02-04	2002-02-04
US40025902P	2002-08-01	2002-08-01
PCT/US2002/031283 WO2003029245A1 (en)	2001-10-01	2002-09-30	Spiro-hydantoin compounds useful as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
HK1063467A1 true HK1063467A1 (en)	2004-12-31

Family

ID=27406458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK04106189.4A HK1063467A1 (en)	2001-10-01	2004-08-18	Spiro-hydantoin compounds useful as anti-inflammatory agents

Country Status (24)

Country	Link
US (4)	US6977267B2 (xx)
EP (1)	EP1432700B1 (xx)
JP (1)	JP4394442B2 (xx)
KR (1)	KR20040041649A (xx)
CN (1)	CN1596253A (xx)
AR (1)	AR036663A1 (xx)
AT (1)	ATE447565T1 (xx)
BR (1)	BR0213025A (xx)
CA (1)	CA2462112A1 (xx)
DE (1)	DE60234264D1 (xx)
ES (1)	ES2339107T3 (xx)
GE (1)	GEP20063767B (xx)
HK (1)	HK1063467A1 (xx)
HR (1)	HRP20040311A2 (xx)
HU (1)	HUP0402338A3 (xx)
IL (1)	IL160990A0 (xx)
IS (1)	IS7197A (xx)
MX (1)	MXPA04002993A (xx)
NO (1)	NO20041339L (xx)
NZ (1)	NZ531870A (xx)
PE (1)	PE20030845A1 (xx)
PL (1)	PL369337A1 (xx)
RS (1)	RS26604A (xx)
WO (1)	WO2003029245A1 (xx)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7550590B2 (en) *	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7700583B2 (en)	2003-04-11	2010-04-20	High Point Pharmaceuticals, Llc	11β-hydroxysteroid dehydrogenase type 1 active compounds
EP2239012A3 (en) *	2003-04-11	2011-06-15	High Point Pharmaceuticals, LLC	Substituted amide derivatives and pharmaceutical uses thereof
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
RU2006107553A (ru) *	2003-08-13	2007-09-20	Такеда Фармасьютикал Компани Лимитед (Jp)	Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз
US20050065144A1 (en) *	2003-09-08	2005-03-24	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
EP1699777B1 (en) *	2003-09-08	2012-12-12	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7199125B2 (en)	2003-10-02	2007-04-03	Bristol-Myers Squibb Company	Spiro-cyclic compounds useful as anti-inflammatory agents
US7314938B2 (en)	2003-11-05	2008-01-01	Sunesis Pharmaceuticals, Inc.	Modulators of cellular adhesion
CA2550447A1 (en)	2003-12-19	2005-07-07	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies
US7718684B2 (en)	2004-02-24	2010-05-18	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies and compounds
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102134231B (zh) *	2004-03-15	2020-08-04	武田药品工业株式会社	二肽基肽酶抑制剂
EP1753730A1 (en) *	2004-06-04	2007-02-21	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP2433943B1 (en)	2004-07-01	2013-09-11	Daiichi Sankyo Company, Limited	Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7375237B2 (en)	2004-08-18	2008-05-20	Bristol-Myers Squibb Company	Pyrrolizine compounds useful as anti-inflammatory agents
TW200616634A (en) *	2004-10-01	2006-06-01	Bristol Myers Squibb Co	Crystalline forms and process for preparing spiro-hydantoin compounds
NZ554906A (en) *	2004-11-10	2011-01-28	Incyte Corp	Lactam compounds and their use as pharmaceuticals
US8110581B2 (en) *	2004-11-10	2012-02-07	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
US20060142319A1 (en) *	2004-12-14	2006-06-29	Bang-Chi Chen	Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7186727B2 (en)	2004-12-14	2007-03-06	Bristol-Myers Squibb Company	Pyridyl-substituted spiro-hydantoin compounds and use thereof
EP2805953B1 (en) *	2004-12-21	2016-03-09	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP2374458A1 (en) *	2005-03-21	2011-10-12	Vicus Therapeutics SPE 1, LLC	Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS
US20080033027A1 (en) *	2005-03-21	2008-02-07	Vicus Therapeutics Spe 1, Llc	Drug combination pharmaceutical compositions and methods for using them
US20090117197A1 (en) *	2005-03-21	2009-05-07	Vicus Therapeutics Llc	Compositions and methods for ameliorating cachexia
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
US20090258862A1 (en) *	2005-08-29	2009-10-15	Colletti Steven L	Niacin receptor agonists, compositions containing such compounds and methods of treatment
CN101374523B (zh)	2005-09-14	2012-04-11	武田药品工业株式会社	用于治疗糖尿病的二肽基肽酶抑制剂
CN102935081B (zh) *	2005-09-14	2015-03-04	武田药品工业株式会社	用于治疗糖尿病的二肽基肽酶抑制剂
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US8222411B2 (en) *	2005-09-16	2012-07-17	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CA2624166A1 (en) *	2005-10-11	2007-04-26	Intermune, Inc.	Inhibitors of viral replication
US8926990B2 (en)	2009-10-13	2015-01-06	Rutgers, The State University Of New Jersey	Treatment and diagnosis of inflammatory disorders and HIV
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
FI2004181T6 (fi)	2006-03-27	2023-09-01		Androgeenireseptorin modulaattori eturauhassyövän ja androgeenireseptoriin liittyvien sairauksien hoitamiseksi
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) *	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
NZ572374A (en)	2006-03-29	2011-12-22	Univ California	Diarylthiohydantoin compounds
US7740064B2 (en)	2006-05-24	2010-06-22	Baker Hughes Incorporated	System, method, and apparatus for downhole submersible pump having fiber optic communications
BRPI0719122A2 (pt)	2006-08-24	2013-12-10	Novartis Ag	Compostos orgânicos
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN101616673A (zh) *	2006-09-13	2009-12-30	武田药品工业株式会社	2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
AU2007299870A1 (en)	2006-09-22	2008-03-27	Novartis Ag	Heterocyclic organic compounds
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CA2672776A1 (en)	2006-12-20	2008-06-26	Novartis Ag	2-substituted 5-membered heterocycles as scd inhibitors
WO2008090944A1 (ja) *	2007-01-25	2008-07-31	Takeda Pharmaceutical Company Limited	スピロ環化合物
US8575167B2 (en)	2007-02-06	2013-11-05	Takeda Pharmaceutical Company Limited	Spiro compounds having stearoyl-CoA desaturase action
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
JP5312324B2 (ja) *	2007-07-19	2013-10-09	株式会社トクヤマ	ヒダントイン環を有する化合物及びその製造方法
EP3167886B1 (en) *	2007-10-19	2020-08-05	Novartis AG	Compositions and methods for treatment of macular edema
JP5535925B2 (ja)	2007-10-26	2014-07-02	ザリージェンツオブザユニバーシティオブカリフォルニア	アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
WO2009061830A1 (en) *	2007-11-06	2009-05-14	Massachusetts Eye & Ear Infirmary	Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
WO2010141330A1 (en)	2009-06-02	2010-12-09	Boehringer Ingelheim International Gmbh	DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
US8779157B2 (en)	2009-09-04	2014-07-15	Vanderbilt University	MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3124481B1 (en)	2010-02-16	2018-03-28	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
JP6243908B2 (ja)	2012-08-23	2017-12-06	アリオスバイオファーマインク．	パラミクソウイルス感染症を治療するための化合物
CN109908114A (zh)	2012-09-26	2019-06-21	阿拉贡药品公司	用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
KR102455034B1 (ko)	2013-08-21	2022-10-13	얀센 바이오파마, 인코퍼레이트.	항바이러스 화합물
AU2015240519B2 (en) *	2014-04-04	2019-08-15	X-Rx, Inc.	Substituted spirocyclic inhibitors of autotaxin
CN107108581B (zh)	2014-08-21	2020-06-23	百时美施贵宝公司	作为强效rock抑制剂的回接苯甲酰胺衍生物
MA41614A (fr)	2015-02-25	2018-01-02	Alios Biopharma Inc	Composés antiviraux
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10610520B2 (en)	2016-03-31	2020-04-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
KR20240096623A (ko)	2017-10-16	2024-06-26	아라곤 파마슈티컬스, 인코포레이티드	비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US20240116864A1 (en) *	2020-12-24	2024-04-11	Orn Almarsson	Xanthophyll derivatives
CN115536494B (zh) *	2022-10-31	2023-12-01	苏州诚和医药化学有限公司	1-(4-溴苯基)-1,4-丁二醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1331757C (en) *	1988-02-29	1994-08-30	Janssen Pharmaceutica Naamloze Vennootschap	5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5346913A (en) *	1992-05-26	1994-09-13	Rohm And Haas Company	N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) *	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) *	1994-01-05	2003-02-21	Hoechst Marion Roussel Inc	New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2741342B1 (fr) *	1995-11-22	1998-02-06	Roussel Uclaf	Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
CA2447475A1 (en)	2001-05-25	2002-12-05	Chu-Biao Xue	Hydantion derivatives as inhibitors of matrix metalloproteinases

2002
- 2002-09-30 EP EP02800414A patent/EP1432700B1/en not_active Expired - Lifetime
- 2002-09-30 JP JP2003532494A patent/JP4394442B2/ja not_active Expired - Fee Related
- 2002-09-30 BR BR0213025-4A patent/BR0213025A/pt not_active IP Right Cessation
- 2002-09-30 RS YU26604A patent/RS26604A/sr unknown
- 2002-09-30 KR KR10-2004-7004778A patent/KR20040041649A/ko not_active Application Discontinuation
- 2002-09-30 GE GE5595A patent/GEP20063767B/en unknown
- 2002-09-30 CN CNA028238540A patent/CN1596253A/zh active Pending
- 2002-09-30 DE DE60234264T patent/DE60234264D1/de not_active Expired - Lifetime
- 2002-09-30 WO PCT/US2002/031283 patent/WO2003029245A1/en active IP Right Grant
- 2002-09-30 AT AT02800414T patent/ATE447565T1/de not_active IP Right Cessation
- 2002-09-30 NZ NZ531870A patent/NZ531870A/en unknown
- 2002-09-30 MX MXPA04002993A patent/MXPA04002993A/es unknown
- 2002-09-30 ES ES02800414T patent/ES2339107T3/es not_active Expired - Lifetime
- 2002-09-30 AR ARP020103695A patent/AR036663A1/es unknown
- 2002-09-30 PL PL02369337A patent/PL369337A1/xx not_active Application Discontinuation
- 2002-09-30 IL IL16099002A patent/IL160990A0/xx unknown
- 2002-09-30 HU HU0402338A patent/HUP0402338A3/hu unknown
- 2002-09-30 CA CA002462112A patent/CA2462112A1/en not_active Abandoned
- 2002-10-01 PE PE2002000971A patent/PE20030845A1/es not_active Application Discontinuation
- 2002-10-01 US US10/262,182 patent/US6977267B2/en not_active Expired - Lifetime
2004
- 2004-03-24 IS IS7197A patent/IS7197A/is unknown
- 2004-03-31 NO NO20041339A patent/NO20041339L/no not_active Application Discontinuation
- 2004-04-01 HR HR20040311A patent/HRP20040311A2/hr not_active Application Discontinuation
- 2004-05-24 US US10/852,576 patent/US7078420B2/en not_active Expired - Lifetime
- 2004-06-16 US US10/869,289 patent/US20040259897A1/en not_active Abandoned
- 2004-06-16 US US10/869,292 patent/US20050004153A1/en not_active Abandoned
- 2004-08-18 HK HK04106189.4A patent/HK1063467A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
GEP20063767B (en)	2006-03-10
HRP20040311A2 (en)	2005-02-28
CA2462112A1 (en)	2003-04-10
AR036663A1 (es)	2004-09-22
ATE447565T1 (de)	2009-11-15
KR20040041649A (ko)	2004-05-17
PL369337A1 (en)	2005-04-18
EP1432700B1 (en)	2009-11-04
US20040248920A1 (en)	2004-12-09
IL160990A0 (en)	2004-08-31
RS26604A (xx)	2006-12-15
BR0213025A (pt)	2004-10-05
NZ531870A (en)	2005-08-26
DE60234264D1 (de)	2009-12-17
US6977267B2 (en)	2005-12-20
CN1596253A (zh)	2005-03-16
MXPA04002993A (es)	2004-07-15
US7078420B2 (en)	2006-07-18
EP1432700A4 (en)	2004-12-22
JP2005510476A (ja)	2005-04-21
PE20030845A1 (es)	2003-10-23
EP1432700A1 (en)	2004-06-30
IS7197A (is)	2004-03-24
HUP0402338A3 (en)	2008-10-28
WO2003029245A1 (en)	2003-04-10
HUP0402338A2 (hu)	2005-02-28
US20040259897A1 (en)	2004-12-23
ES2339107T3 (es)	2010-05-17
US20040009998A1 (en)	2004-01-15
NO20041339D0 (no)	2004-03-31
NO20041339L (no)	2004-05-24
US20050004153A1 (en)	2005-01-06
JP4394442B2 (ja)	2010-01-06

Legal Events

Date

Code

Title

Description

2010-07-30

AM

Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM MAGALI JEANNINE BLADINE MAILLET TO MAGAILI JEANNINE BLANDINE MAILLET.

Effective date: 20100722

2015-04-24

PC

Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140930

Publication	Publication Date	Title
HK1063467A1 (en)	2004-12-31	Spiro-hydantoin compounds useful as anti-inflammatory agents
IL174917A0 (en)	2006-08-20	Compounds useful as anti-inflammatory agents
AU2002349297A8 (en)	2003-06-17	Statin-like compounds
GB0101996D0 (en)	2001-03-14	Organtic compounds
GB0127145D0 (en)	2002-01-02	Compounds
GB0102668D0 (en)	2001-03-21	Compounds
MXPA03009361A (es)	2004-01-29	Compuestos de urea utilies como agentes anti-inflamatorios.
GB0108102D0 (en)	2001-05-23	Compounds
GB0102673D0 (en)	2001-03-21	Compounds
GB0102665D0 (en)	2001-03-21	Compounds
PL369829A1 (en)	2005-05-02	Substituted 1h-quinolin-2-one compounds
AU2003282510A8 (en)	2004-05-04	Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
EP1458669A4 (en)	2008-10-29	ACTIVE COMPOUNDS ON THE NEUROLOGICAL PLAN
EP1395259A4 (en)	2005-01-26	USE OF URAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS
GB0119473D0 (en)	2001-10-03	Compounds
AU2001253517A1 (en)	2002-10-28	Compounds useful as anti-inflammatory agents
GB0105098D0 (en)	2001-04-18	Compounds
GB0109999D0 (en)	2001-06-13	Therapeutically useful compounds
GB0125123D0 (en)	2001-12-12	Therapeutically useful compounds
GB0117145D0 (en)	2001-09-05	Therapeutically useful compounds
GB0107643D0 (en)	2001-05-16	Therapeutically useful compounds
GB0127159D0 (en)	2002-01-02	Therapeutically useful compounds
GB0111645D0 (en)	2001-07-04	Therapeutically useful compounds
GB0111642D0 (en)	2001-07-04	Therapeutically useful compounds
GB0107644D0 (en)	2001-05-16	Therapeutically useful compounds